Predictors of the efficiency of neoadjuvant hormone therapy

Semiglazov V.F.

FGBU "NII onkologii im. N.N. Petrova"

Pen'kov K.D.

FGBU "NII onkologii im. N.N. Petrova"

Manikhas A.G.

SPbGBUZ "Gorodskoĭ klinicheskiĭ onkologicheskiĭ dispanser"

Paltuev R.M.

FGBU "NII onkologii im. N.N. Petrova" Minzdravsotsrazvitiia Rossii, Sankt-Peterburg

Skvortsov V.V.

SPbGBUZ "Gorodskoĭ klinicheskiĭ onkologicheskiĭ dispanser"

Raskin G.G.

SPbGBUZ "Gorodskoĭ klinicheskiĭ onkologicheskiĭ dispanser"

Predictors of the efficiency of neoadjuvant hormone therapy

Authors:

Semiglazov V.F., Pen'kov K.D., Manikhas A.G., Paltuev R.M., Skvortsov V.V., Raskin G.G.

More about the authors

Journal: P.A. Herzen Journal of Oncology. 2013;2(2): 43‑45

Downloaded: 15

Download PDF (RU)

Contact the author

Table of contents

To cite this article:

Semiglazov VF, Pen'kov KD, Manikhas AG, Paltuev RM, Skvortsov VV, Raskin GG. Predictors of the efficiency of neoadjuvant hormone therapy. P.A. Herzen Journal of Oncology. 2013;2(2):43‑45. (In Russ.)

Подписка 2025-2 (P.A. Herzen Journal of Oncology)

Close metadata

Recommended articles:

Reconstructive plastic surgery in combined treatment of breast cancer: predictive risk factors of complications and reconstruction failure. P.A. Herzen Journal of Oncology. 2024;(3):13-19

Targeted lymphadenectomy with sentinel lymph node biopsy in patients with breast cancer cT1-3N1M0 after neoadjuvant polychemotherapy. P.A. Herzen Journal of Oncology. 2024;(3):73-78

Breast cancer: types of implantable materials for replacement of postresection defects. P.A. Herzen Journal of Oncology. 2024;(3):85-89

Leading trends in breast cancer incidence in the Republic of Crimea. P.A. Herzen Journal of Oncology. 2024;(4):42-47

Complications after one-stage and two-stage breast reconstruction depending on the method of reconstruction and risk factors. Plastic Surgery and Aesthetic Medicine. 2024;(2):16-21

Perforator fasciocutaneous flaps in resections for breast cancer. Plastic Surgery and Aesthetic Medicine. 2024;(2):81-86

The impact of artificial intelligence on double reading of mammograms. Russian Journal of Preventive Medicine. 2024;(5):32-37

Intrathecal chemotherapy for leptomeningeal metastases in patients with breast cancer. Burdenko's Journal of Neurosurgery. 2024;(3):31-37

Expression of transferrin receptor 1 and β1-integrins correlates with estrogen receptor status and immune infiltration in breast cancer. Russian Journal of Archive of Pathology. 2024;(4):23-30

Indocyanine green is an integral part of breast reconstructive surgery using perforator flaps. Pirogov Russian Journal of Surgery. 2024;(8):34-40

This retrospective trial enrolled 440 postmenopausal estrogen and/or progesterone receptor positive (T2N1-2, T3N0-1, T4N0M0) patients who had previously (2001-2011) received neoadjuvant hormone therapy with aromatase inhibitors (anastrozole, letrozole, exemestane, n = 211 or tamoxifen (n = 229). There was a high objective response in both groups at a high level of estrogen receptors. During a 60-month median follow-up, distant metastases were found in 25.5% in the tamoxifen group and in 12% in the aromatase inhibitor group at moderate and high level of cyclin D1.

Keywords:

breast cancer

hormone therapy

aromatase inhibitors

receptor coexpressio

Authors:

Semiglazov V.F.

FGBU "NII onkologii im. N.N. Petrova"

Pen'kov K.D.

FGBU "NII onkologii im. N.N. Petrova"

Manikhas A.G.

SPbGBUZ "Gorodskoĭ klinicheskiĭ onkologicheskiĭ dispanser"

Paltuev R.M.

FGBU "NII onkologii im. N.N. Petrova" Minzdravsotsrazvitiia Rossii, Sankt-Peterburg

Skvortsov V.V.

SPbGBUZ "Gorodskoĭ klinicheskiĭ onkologicheskiĭ dispanser"

Raskin G.G.

SPbGBUZ "Gorodskoĭ klinicheskiĭ onkologicheskiĭ dispanser"

List of references:

Ring A., Smith I., Ashley S., Fulford L.G., Lakhani S.R. Oestrogen receptor status, pathological complete response and prognosis in patient receiving neoadjuvant chemotherapy for early breast cancer. Br. J. Cancer. 2004; 91 (12): 2012-17.
Colleoni M., Viale G., Zahrieh D., Pruneri G., Gentilini O., Veronesi P. et al. Chemotherapy is more effective in patients with breast cancer not expressing steroid hormone receptors: a study of preoperative treatment. Clin. Cancer Res. 2004; 10 (19): 6622-8.
Colleoni M., Viale G., Zahrieh D., Bottiglieri L., Gelber R., Veronesi P. et al. Expression of ER, PgR, HER1, HER2, and response: a study of preoperative chemotherapy. Ann. Oncol. 2008; 19 (3): 465-72.
Semiglazov V., Kletsel A., Semiglazov V., Zhiltzova E., Ivanov V., Dashyan G. et al. Exemestane (E) vs tamoxifen (T) as neoadjuvant endocrine therapy for postmenopausal women with ER + breast cancer (T2N1-2, T3N0-1, T4N0M0) [abstract]. J. Clin. Oncol.: ASCO Annual Meeting Proceedings. 2005; 23 (16S, Pt 1-2, Suppl.): 530.
Semiglazov V.F., Semiglazov V.V., Dashyan G., Ziltsova E., Ivanov V., Bozhok A. et al. Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer. Cancer. 2007; 110: 244-54.
Johnston S., Pippen J.Jr., Pivot X., Lichinitser M., Sadeghi S., Dieras V. et al. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. J. Clin. Oncol. 2009; 27 (33): 5538-46.
Baselga J., Semiglazov V., van Dam P., Manikhas A., Bellet M., Mayordomo J. et al. Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer. J. Clin. Oncol. 2009; 27 (16): 2630-7.

Close metadata